🔗 Share this article The Global Health Body Issues Concern Over Critical Scarcity of Weight-Loss Jabs Fewer than a tenth of patients eligible to benefit from GLP-1 drugs including Wegovy are able to get them, caution the global health agency as it issues its inaugural guidance on the medications. Considering more than one billion people worldwide now classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication. Per projections, more than two billion could be living with obesity by 2030 without intervention. "Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with holistic and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are significant hurdles to broad access to the treatments that can help people shift significant weight, says the agency. Skinny Jab Supply Crisis Even under the present best projected case, the production of such drugs might only reach around 100 million people – under 10% of the global need, according to the health organization. The recommendation urges countries and companies to increase availability, by strategies like licensing agreements. The intellectual property rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in multiple countries in 2026. The Way Weight-Loss Jabs Work GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so individuals consume fewer calories. People commonly see weight reduction after several weeks of beginning the once-weekly jabs. Research indicates people may regain a significant portion after a year of discontinuing the drug, as their usual appetite resume. Being above a healthy weight elevates your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Obesity affects people in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
Fewer than a tenth of patients eligible to benefit from GLP-1 drugs including Wegovy are able to get them, caution the global health agency as it issues its inaugural guidance on the medications. Considering more than one billion people worldwide now classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication. Per projections, more than two billion could be living with obesity by 2030 without intervention. "Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with holistic and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are significant hurdles to broad access to the treatments that can help people shift significant weight, says the agency. Skinny Jab Supply Crisis Even under the present best projected case, the production of such drugs might only reach around 100 million people – under 10% of the global need, according to the health organization. The recommendation urges countries and companies to increase availability, by strategies like licensing agreements. The intellectual property rights on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in multiple countries in 2026. The Way Weight-Loss Jabs Work GLP-1 drugs imitate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so individuals consume fewer calories. People commonly see weight reduction after several weeks of beginning the once-weekly jabs. Research indicates people may regain a significant portion after a year of discontinuing the drug, as their usual appetite resume. Being above a healthy weight elevates your risk for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Obesity affects people in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.